SCHEMBL6568357

SCHEMBL6568357

O=C(NN=Cc1ccc(O)cc1O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.78
KDM4E B2RXH2 4/20 0.78
LMNA P02545 4/20 0.78
POLB P06746 3/20 0.78
HTT P42858 3/20 0.78
PTBP1 P26599 2/20 0.78
SMN1; SMN2 Q16637 2/20 0.78
TDP1 Q9NUW8 1/20 0.78
MAPT P10636 6/20 0.72
MEN1 O00255 5/20 0.61
HSP90AA1 P07900 1/20 0.60
GAA P10253 1/20 0.60
HPGD P15428 1/20 0.60
ALOX12 P18054 1/20 0.60
SIRT1 Q96EB6 1/20 0.60
NPC1 O15118 2/20 0.59
RAB9A P51151 2/20 0.59
NTRK1 P04629 1/20 0.57
ALPL P05186 1/20 0.56
ALPI P09923 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6568354 1.00 KMT2A (0.78) KMT2AKDM4ELMNAPOLBHTT
SCHEMBL6571440 0.91 KDM4E (0.78) KMT2AKDM4ELMNAPOLBHTT
SCHEMBL6571437 0.91 KDM4E (0.78) KMT2AKDM4ELMNAPOLBHTT
SCHEMBL22179617 0.88 KMT2A (0.75) KMT2AKDM4ELMNAPOLBHTT
SCHEMBL20587601 0.88 KMT2A (0.75) KMT2AKDM4ELMNAPOLBHTT
SCHEMBL20587604 0.88 KMT2A (0.75) KMT2AKDM4ELMNAPOLBHTT
SCHEMBL6749907 0.88 KDM4E (0.78) KMT2AKDM4ELMNAPOLBHTT
SCHEMBL6571712 0.88 KMT2A (1.00) KMT2AKDM4ELMNAPOLBHTT
SCHEMBL6749902 0.88 KDM4E (0.78) KMT2AKDM4ELMNAPOLBHTT
SCHEMBL6571710 0.88 KMT2A (1.00) KMT2AKDM4ELMNAPOLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US claimed
CN-106957242-A A kind of schiff base compounds and preparation method thereof and pharmaceutical applications 四川省人民医院 2017-07-18 CN disclosed
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US disclosed
EP-1404644-A2 NOVEL HYDRAZONES Arpida AG, (CH) 2004-04-07 EP disclosed
WO-2002070464-A2 HYDRAZONES AND THEIR THERAPEUTIC USE ARPIDA AG (CH) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110963-A1 Novel hydrazones H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HK1, MPO KMT2A 3368/4885KDM4E 3228/4885LMNA 4156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.